VolitionRx Q3 Revenue Up 157% to $1.6M; CEO Pay Cut to 50% of Original
VNRX sits 18% above its 52-week low of $0.156 on light trading volume (0.1× avg).
Summary
VolitionRx reported Q3 2026 revenue of about $1.6 million, up 157%, and a narrowed $3.3 million operating loss, with roughly $2.4 million in cash after prepaying a $7.5 million convertible note. The CEO cut his base salary to 50% of its original level and the board halved its cash fees until a substantial licensing agreement is signed.
Key Events · Earnings and Guidance · VNRX
-
Q3 Revenue Jumps 157% to $1.6M
Third quarter 2026 revenue was approximately $1.6 million versus $0.6 million a year earlier, driven by increased recognition of deferred revenue.
-
Losses Narrow but Cash Is Thin
Operating loss improved 35% to $3.3 million and net loss was $3.8 million, yet cash stood at only about $2.4 million on September 30, 2026, after prepaying a $7.5 million convertible note in cash.
-
ATM Funded the Quarter
The company received approximately $5.2 million in net proceeds from its at-the-market facility during Q3, meaning equity issuance is currently funding operations.
-
CEO and Board Cut Pay in Half
The CEO's base salary is now 50% of its original level effective November 1, 2026, and the chairman and entire board reduced cash fees by at least 50%, tied to closing a substantial licensing agreement.
Analysis · VNRX · Life Sciences
Revenue more than doubled to about $1.6 million while operating loss narrowed 35% to $3.3 million, but the company still burned cash and ended the quarter with only about $2.4 million on hand after prepaying a $7.5 million convertible note. The CEO and board cutting their own pay by half until a substantial licensing deal closes shows how thin the runway is — the licensing negotiations are now the company's lifeline, not a nice-to-have.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNRX was trading at $0.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.16 to $8.13. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.